Marker Therapeutics Q2 FY26 net loss narrows 55% to USD 1.83 million - MRKR News | RalliesMarker Therapeutics Q2 FY26 net loss narrows 55% to USD 1.83 million
M
MRKR• Quarterly results improve as expenses fall
- Marker Therapeutics posted a net loss of USD 1.83 million, narrowing 55% from the prior-year quarter.
- Operating loss improved to USD 2.62 million as operating expenses fell 49% to USD 2.62 million.
- R&D spending dropped 65% to USD 1.48 million on lower clinical trial, consulting, and other clinical costs.
- G&A rose 21% to USD 1.14 million, driven by headcount-related costs including stock-based compensation.
- Cash, cash equivalents, and restricted cash totaled USD 11.92 million; funding runway projected into Q2 2027, excluding additional grant receipts.
BWB
•
